Novartis International AG is a Swiss multinational pharmaceutical company headquartering in Basle (Switzerland). It is one of the major pharmaceutical companies by market capitalization and sales. Novartis is engaged in the production of such medications as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), Imatinib mesylate (Gleevec), cyclosporine (Neoral / Sandimmun), Letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), etc. In 1996, Ciba-Geigy consolidated with Sandoz; pharmaceutical and agrochemical sectors of both companies have formed an independent entity of Novartis. Other Ciba-Geigy and Sandoz businesses were sold or like Ciba Specialty Chemicals made independent entities. The Sandoz brand withdrew from the market in three years, but it got back in 2003 when Novartis integrated its generic producing business into an affiliated company under the title Sandoz. Novartis is a full-fledged member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) as well as The Pharmaceutical Research and Manufacturers of America (PhRMA).
Not all companies have really great missions. Medtronic, however, does have it: it is striving to help sick people recover and live better. Medtronic, based in the US, is a global leading company in developing and producing medical technologies, devices, and equipment used by millions of people throughout the world. The company has 44 factories and 25 research centers across the globe. Its 45,000 employees are working on a daily basis to improve the current treatment methods and create new ones. Since its inception, Medtronic created over 150,000 various products that help to treat over 50 chronic diseases. The experts report that around 6 to 7 million lives are saved yearly thanks to Medtronic's technologies and equipment.
Nyní budete vždy vědět, do kterých akcií je výhodnější investovat